Log In
Print
BCIQ
Print
Print this Print this
 

CMV gB/MF59

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionVaccine consisting of recombinant human cytomegalovirus (CMV) glycoprotein B with MF59 adjuvant
Molecular Target Human cytomegalovirus (CMV) glycoprotein B
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today